Aveanna Healthcare Holdings, Inc.
No SEC Form 4 filings for $AVAH in the last 30 days.
See all $AVAH insider activity →Aveanna Healthcare Holdings (AVAH) reported Q2 results and raised its full-year 2026 revenue outlook, citing operational gains in home care segments. The stock rose 9.12% in one day. A valuation narrative sets fair value at $9.95 versus a $12.32 close and flags risks including Medicaid/Medicare reliance and $1.47b variable-rate debt.
Aveanna Healthcare (AVAH) shares rose about 10.5% in pre-open after the company raised its 2026 revenue outlook to more than $2.68B from prior guidance of $2.63B to $2.65B. Aveanna reported Q2 adjusted EPS of $0.22 vs $0.17 expected, and revenue of $670.5M vs $638.6M expected, citing early contribution from its Family First Homecare acquisition.
Aveanna Healthcare Holdings, Inc. (AVAH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 avah-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVEANNA HEALTHCARE HOLDINGS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND REVISED 2026 GUIDANCE • Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period • Second Quarter Net income was $40.3 m
Over the past 7 days, alphai's AI scored 3 news stories mentioning AVAH (Aveanna Healthcare Holdings, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent AVAH coverage spans earnings, sector analysis and mergers & acquisitions.
Guidance lift and operational momentum are supportive, but the article flags valuation risk and funding and leverage concerns.
Raised full-year revenue outlook plus a Q2 beat tied to Family First Homecare integration is a near-term positive catalyst for AVAH.
Guidance raise plus higher Q2 revenue and Adjusted EBITDA suggests improving operating momentum and supports upward repricing versus prior expectations.
Board/committee leadership changes are typically low-to-moderate impact, but can affect governance optics and committee oversight continuity.
Analyst list addition is a sentiment catalyst tied to an upcoming earnings date, but it is not a fundamental disclosure.
alphai scores every news story that mentions AVAH with an AI model for sentiment and relevance, and aggregates insider trades from Aveanna Healthcare Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aveanna Healthcare Holdings (AVAH) reported Q2 results and raised its full-year 2026 revenue outlook, citing operational gains in home care segments. The stock rose 9.12% in one day. A valuation narrative sets fair value at $9.95 versus a $12.32 close and flags risks including Medicaid/Medicare reliance and $1.47b variable-rate debt.
6 min readAveanna Healthcare (AVAH) shares rose about 10.5% in pre-open after the company raised its 2026 revenue outlook to more than $2.68B from prior guidance of $2.63B to $2.65B. Aveanna reported Q2 adjusted EPS of $0.22 vs $0.17 expected, and revenue of $670.5M vs $638.6M expected, citing early contribution from its Family First Homecare acquisition.
3 min readAveanna Healthcare Holdings, Inc. (AVAH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 avah-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVEANNA HEALTHCARE HOLDINGS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND REVISED 2026 GUIDANCE • Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period • Second Quarter Net income was $40.3 m
4 min readAveanna Healthcare Holdings, Inc. (AVAH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001832332 0001832332 2026-08-05 2026-08-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05
2 min readRaymond James updated its August healthcare top picks, adding Aveanna Healthcare (AVAH) ahead of its Aug. 13 earnings, and Carriage Services (CSV) after a ~20% decline since April, citing stabilizing funeral trends and valuation around 8x 2027 estimated EBITDA. It also added Viking Therapeutics (VKTX) for upcoming clinical readouts.
2 min readThe article says investors are rotating from highly valued AI infrastructure toward healthcare, citing a Bank of America survey and recent sector performance. It highlights three healthcare stocks: Aurinia Pharmaceuticals (AUPH) with Q1 revenue $77.7M and EPS $0.25; Fortrea (FTRE) raising full-year sales and adjusted EBITDA; and Aveanna (AVAH) after a $175.5M acquisition, guiding FY revenue $2.63B-$2.65B.
6 min readBain Capital, KKR and KV Asia have been shortlisted to buy a 20–25% minority stake in Malaysia’s Avisena Healthcare, valuing the company at about RM1.5 billion (US$368m), according to two sources. Binding bids are due by end-July. The stake is estimated at RM300–400m. KKR and Bain declined comment; Avisena and KV Asia did not respond.
3 min readBain Capital, KKR and KV Asia Capital were shortlisted to buy a minority stake (about 20%–25%) in Malaysia’s Avisena Healthcare, valuing the firm at around 1.5 billion ringgit ($368m), said two sources. Binding bids are due by end-July; the stake is estimated at 300–400m ringgit. Avisena serves 250,000+ patients annually.
4 min readWILLIAMS ROBERT M JR sold 3,000,000 indirectly-held shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $8.01 ($24.03M total) across 3 trades on 2026-06-30.
2 min readVIGANO PAUL R sold 3,000,000 indirectly-held shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $8.01 ($24.03M total) across 3 trades on 2026-06-30.
2 min read
